Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Glutathione S-transferase P1 and DNA Polymorphisms with the Response to Chemotherapy and the Prognosis of Bone Tumor

  • Yang, Li-Min (Department of Orthopaedics, The First Affiliated Hospital of Liaoning Medical College) ;
  • Li, Xiu-Hua (Department of Orthopaedics, The First Affiliated Hospital of Liaoning Medical College) ;
  • Bao, Cui-Fen (Central Laboratory of Liaoning Medical University)
  • Published : 2012.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Osteosarcoma is the most common primary bone malignancy in children and adolescents, and its clinical outcome is poor. We evaluated the response of GSTP1, ERCC1 and ERCC2 to chemotherapy among osteosarcoma patients, and the role of these genes on the prognosis of osteosarcoma. 187 patients with osteosarcoma were administered with methotrexate, cisplatin/adriamycin, actinomycin D, cyclophosphamide, or vincristine treatment. GSTP1, ERCC1 and ERCC2 polymorphism was genotyped by PCR-RFLP assay. The results showed the average survival time of 187 patients were 38.4 months. 97 patients showed response to neoadjuvant chemotherapy. The GSTP1 Val and ERCC2 A/A genotypes had significantly higher rates of response to chemotherapy, with adjusted OR (95% CI) of 2.19 (1.15-6.21) and 2.88 (1.14-13.25). Individuals with ERCC2 A/A genotype were likely to have a lower risk of death from oseosarcoma, and the adjusted HR was 0.32 (0.13-0.95). Our study indicated test of GSTP1 and ERCC2 Lys751Gln polymorphisms might be a candidate pharmacogenomic factors to be explored in the future to identify the osteosarcoma patients who might benefit from chemotherapy.

Keywords

References

  1. Caronia D, Patino-Garcia A, Milne RL, et al (2009). Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J, 9, 347-53. https://doi.org/10.1038/tpj.2009.19
  2. Fuchs B, Zhang K, Schabel A, et al (2001). Identification of twenty-two candidate markers for human osteogenic sarcoma. Gene, 278, 245-52. https://doi.org/10.1016/S0378-1119(01)00731-4
  3. Goode EL, Ulrich CM, Potter JD (2002). Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol. Biomarkers Prev, 11, 1513-30.
  4. Hao T, Feng W, Zhang J, Sun YJ, Wang G (2012). Association of Four ERCC1 and ERCC2 SNPs with Survival of Bone Tumour Patients. Asian Pac J Cancer Prev, 13, 3821-4. https://doi.org/10.7314/APJCP.2012.13.8.3821
  5. Hengstler JG, Arand M, Herrero ME, et al (1998). Polymorphisms of N-acetyltransferases, glutathione S-transferases, microsomal epoxide hydrolase, and sulfotransferases: influence on cancer susceptibility. Recent Results Cancer Res, 154, 47-85. https://doi.org/10.1007/978-3-642-46870-4_4
  6. Ketterer B (1988). The protective role of glutathione transferases in mutagenesis and carcinogenesis. Mutat Res, 202, 343-61. https://doi.org/10.1016/0027-5107(88)90197-2
  7. Kweekel DM, Gelderblom H, Antonini NF, et al (2009). Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. Eur J Cancer, 45, 572-8. https://doi.org/10.1016/j.ejca.2008.10.015
  8. Mirabello L, Troisi RJ, Savage SA (2009). International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer, 125, 229-234. https://doi.org/10.1002/ijc.24320
  9. Pasello M, Manara MC, Michelacci F, et al (2011). Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: a promising therapeutic strategy. Anal Cell Pathol (Amst), 34, 131-45. https://doi.org/10.1155/2011/414985
  10. Pasello M, Michelacci F, Scionti I, et al (2008). Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma. Cancer Res, 68, 6661-8. https://doi.org/10.1158/0008-5472.CAN-07-5840
  11. Riddick DS, Lee C, Ramji S, et al (2005). Cancer chemotherapy and drug metabolism. Drug Metab Dispos, 33, 1083-96. https://doi.org/10.1124/dmd.105.004374
  12. Stoehlmacher J, Park DJ, Zhang W, et al (2002). Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst, 94, 936-42. https://doi.org/10.1093/jnci/94.12.936
  13. U.S. Cancer Statistics Working Group (2009). United States Cancer Statistics: 2004 Incidence and Mortality. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute. Available at: http://www.cdc. gov/cancer/npcr/npcrpdfs/US_Cancer_Statistics_2004_Incidence_and_Mortality.pdf. Oct. 2011.
  14. Windsor RE, Strauss SJ, Kallis C, et al (2012). Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study. Cancer, 118, 1856-67. https://doi.org/10.1002/cncr.26472
  15. Wang X, Zuckerman B, Pearson C, et al (2002). Maternal cigarette smoking, metabolic gene polymorphism, and infant birth weight. JAMA, 287, 195-202. https://doi.org/10.1001/jama.287.2.195
  16. Zhang SL, Mao NF, Sun JY, Shi ZC, Wang B, Sun YJ (2012). Predictive potential of glutathione S-transferase polymorphisms for prognosis of osteosarcoma patients on chemotherapy. Asian Pac J Cancer Prev, 13, 2705-9. https://doi.org/10.7314/APJCP.2012.13.6.2705
  17. Zimniak P, Nanduri B, Pikula S, et al (1994). Naturally occurring human glutathione S-transferase GSTP-1 isoforms with isoleucin and valine in position 104 differ in enzymic properties. Eur J Biochem, 224, 893-9. https://doi.org/10.1111/j.1432-1033.1994.00893.x

Cited by

  1. The association of glutathione S-transferase polymorphisms in patients with osteosarcoma: evidence from a meta-analysis vol.24, pp.3, 2014, https://doi.org/10.1111/ecc.12197
  2. ERCC polymorphisms and prognosis of patients with osteosarcoma vol.35, pp.10, 2014, https://doi.org/10.1007/s13277-014-2322-1
  3. Predictive potential of ABCB1, ABCC3, and GSTP1 gene polymorphisms on osteosarcoma survival after chemotherapy vol.35, pp.10, 2014, https://doi.org/10.1007/s13277-014-1917-x
  4. Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy vol.35, pp.4, 2014, https://doi.org/10.1007/s13277-013-1378-7
  5. Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy? vol.5, pp.1664-8021, 2014, https://doi.org/10.3389/fgene.2014.00391
  6. Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma vol.11, pp.9, 2015, https://doi.org/10.1517/17425255.2015.1060220
  7. Translesion Polymerase Genes Polymorphisms and Haplotypes Influence Survival of Osteosarcoma Patients vol.19, pp.3, 2015, https://doi.org/10.1089/omi.2014.0159
  8. Research progress on the multidrug resistance mechanisms of osteosarcoma chemotherapy and reversal vol.36, pp.3, 2015, https://doi.org/10.1007/s13277-015-3181-0
  9. Genetic variations in the PRKCG gene and osteosarcoma risk in a Chinese population: a case-control study vol.36, pp.7, 2015, https://doi.org/10.1007/s13277-015-3182-z
  10. Genetic polymorphisms in ERCC1 and ERCC2 genes are associated with response to chemotherapy in osteosarcoma patients among Chinese population: a meta-analysis vol.15, pp.1, 2017, https://doi.org/10.1186/s12957-017-1142-3
  11. The pharmacogenomics of osteosarcoma vol.17, pp.1, 2017, https://doi.org/10.1038/tpj.2016.45
  12. Haplotype analysis on relationship of ERCC2 and ERCC3 gene polymorphisms with osteosarcoma risk in Chinese young population vol.28, pp.5-6, 2017, https://doi.org/10.1007/s00335-017-9693-8
  13. Molecular mechanisms of chemoresistance in osteosarcoma (Review) vol.7, pp.5, 2014, https://doi.org/10.3892/ol.2014.1935
  14. Predictive Value of Ercc1 and Xpd Polymorphisms for Clinical Outcomes of Patients Receiving Neoadjuvant Therapy vol.94, pp.39, 2015, https://doi.org/10.1097/MD.0000000000001593